Work

1453P Phase II study of belzutifan plus cabozantinib for previously treated advanced renal cell carcinoma (RCC): Update from cohort 2 of LITESPARK-003

Year: 2022

Type: article

Study design: Clinical Trial

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2022.07.1556

Authors: D.F. McDermott, T.K. Choueiri, S. Tykodi, J. Merchan, A. Roy, R. Perini, D. Vickery, T. Bauer

Institutions: Beth Israel Deaconess Medical Center, Dana-Farber Cancer Institute, University of Washington, Fred Hutch Cancer Center, University of Miami Health System, Merck & Co., Inc., Rahway, NJ, USA (United States), Sarah Cannon, Tennessee Oncology

Language: English

Topic: Renal cell carcinoma treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W4295836932

FWCI: 0.422

Cites:

Cited by: 3

Related to: 10